Abstract:Tau phosphorylation at specific Alzheimer's disease (AD)‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. ATP levels were reduced in cells expressing either tau pseudophosphorylated at S396/404 (2EC) or T231/S235 (2EM), and ROS production increased in 2EC cells during oxidation of succinate compared to wild type (T4)‐expressing cells. Thapsigargin reduced mitochondrial membrane potential (Ψm) and increased ROS production in both 2EC and 2EM cells. Altogether, these findings extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD. The thickness of the green arrows corresponds with the magnitude of effect. The longer red and black arrows represent experiments conducted with stressors and in the basal state, respectively. Phosphorylation of tau at sites associated with Alzheimer's disease (AD) likely plays a role in the disease progression. Mitochondrial impairment, correlating with increased presence of phosphorylated tau, has been identified as a contributing factor to neurodegenerative processes in AD. However, how tau phosphorylated at specific sites impacts mitochondrial function has not been fully defined. We examined how AD‐relevant phosphomimetics of tau impact selected aspects of mitochondrial biology. To mimic phosphorylation at AD‐associated sites, the serine/threonine (Ser/Thr) sites in wild‐type green fluorescent protein (GFP)‐tagged tau (T4) were converted to glutamic acid (E) to make pseudo‐phosphorylated GFP‐tagged Ser‐396/404 (2EC) and GFP‐tagged Thr‐231/Ser‐235 (2EM) constructs. These constructs were expressed in immortalized mouse hippocampal neuronal cell lines, and their impact on specific mitochondrial functions and responses to stressors were measured. Phosphomimetic tau altered mitochondrial distribution. Specifically, mitochondria accumulated in the soma of cells expressing either 2EC or 2EM and neurite‐like extensions in 2EC cells were shorter. Additionally, adenosine triphosphate levels were reduced in both 2EC‐ and 2EM‐expressing cells, and reactive oxygen species (ROS) production increased in 2EC cells during oxidation of succinate when compared to T4‐expressing cells. Thapsigargin reduced mitochondrial membrane potential and increased ROS production in both 2EC and 2EM cells relative to T4 cells, with no significant difference in the effects of rotenone. These results show that tau phosphorylation at specific AD‐relevant epitopes negatively affects mitochondria, with the extent of dysfunction and stress response varying according to the sites of phosphorylation. Altogether, these findings show that phosphorylated tau increases mitochondrial susceptibility to stressors and extend our understanding of potential mechanisms whereby phosphorylated tau promotes mitochondria dysfunction in tauopathies, including AD.

A mitochondria cluster at the proximal axon initial segment controls axodendritic TAU trafficking in rodent primary and human iPSC-derived neurons

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Hyperphosphorylated Human Tau Accumulates at the Synapse, Localizing on Synaptic Mitochondrial Outer Membranes and Disrupting Respiration in a Mouse Model of Tauopathy

Mitophagy coordination with retrograde transport ensures the integrity of synaptic mitochondria

Axodendritic sorting and pathological missorting of Tau are isoform-specific and determined by axon initial segment architecture

Mitochondrial bioenergetics stimulates autophagy for pathological MAPT/Tau clearance in tauopathy neurons

Tau Accumulation Impairs Mitophagy Via Increasing Mitochondrial Membrane Potential and Reducing Mitochondrial Parkin.

Developmental Regulation of Microtubule‐based Trafficking and Anchoring of Axonal Mitochondria in Health and Diseases

Effects of P301L-TAU on post-translational modifications of microtubules in human iPSC-derived cortical neurons and TAU transgenic mice

Broad activation of the PRKN pathway triggers synaptic failure by disrupting synaptic mitochondrial supply in early tauopathy

Site‐specific phosphorylation of tau impacts mitochondrial function and response to stressors

Mitochondrial bioenergetics stimulates autophagy for pathological tau clearance in tauopathy neurons

Targeting Tau Mitigates Mitochondrial Fragmentation and Oxidative Stress in Amyotrophic Lateral Sclerosis

Axonal Tau sorting depends on the PRR2 domain and 0N4R-specific interactions hint at distinct roles of Tau isoforms in synaptic plasticity

Truncated Tau Induces Mitochondrial Transport Failure Through the Impairment of TRAK2 Protein and Bioenergetics Decline in Neuronal Cells

Mitochondrial Dysfunction Triggers Synaptic Deficits Via Activation of P38 MAP Kinase Signaling in Differentiated Alzheimer's Disease Trans-Mitochondrial Cybrid Cells.

Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology

Acute Impairment of Mitochondrial Trafficking by Beta-Amyloid Peptides in Hippocampal Neurons

Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration

The disease-causing tau V337M mutation induces tau hypophosphorylation and perturbs axon morphology pathways

Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity